Arnaud Pharmaceutical Lysooma Virus Product Pelareorep (AN1004) approved by NMPA for clinical trial

today, theof theMedicines (http://announced that its ossotic virus product Pelareorep (AN1004) has been approved by the National FoodMedicines(http://Regulatory Authority (NMPA) clinicaltrial(http://approval, will be conducted in China, Pelareep combined with yew alcohol treatment of advanced/metastatic breast cancer open, randomized, multi-center Phase III clinical trialAbout PelareorepPelareorep is the world's fastest-developing, intravenously administered lysomal virus product, and its phase II clinical trial of therapeutically metastatic breast cancer found that Pelareorep and yew alcohol were combined with er plus PR/HER2-breast cancer patients with a doubling overall survival rate (21.August vs10.8)the U.SFDA(http://has approved its Phase III clinical trial for the treatment of metastatic breast cancer using "special program assessment" and granting it fast-track eligibilityArnold Pharmaceuticals' innovativedrug(http:// isdeveloped to turn cancer into a non-lethal disease and even cure, said Lu Yang, chairman and CEO of Arnold PharmaLu Yang, chairman and CEO ofAnarnpharma, said thecompany will join and launch Phase III clinical trials(http://global partner, Oncolytics Canada, to begin APlareep Phase III clinical study